Company Overview

Defence Therapeutics Inc. (DTC) is a Canadian biotechnology company focused on the development of next-generation immunotherapies and vaccines, primarily targeting oncology and infectious diseases. The company operates within the biopharmaceutical and life sciences industries, with a core emphasis on improving the intracellular delivery and efficacy of therapeutic agents.

The company’s primary value proposition is its proprietary AccuTOX® and Accum™ technologies, which are designed to enhance antigen delivery into target cells, thereby strengthening immune responses. These technologies underpin DTC’s therapeutic pipeline, which includes cancer immunotherapies and vaccine platforms. Defence Therapeutics positions itself as a platform-based developer, aiming to out-license or co-develop its technologies with larger pharmaceutical partners. The company traces its origins to academic research collaborations in Canada and has evolved from a technology-focused startup into a publicly listed clinical-stage biotechnology firm.

Business Operations

Defence Therapeutics generates value through the research, development, and preclinical advancement of immunotherapy candidates based on its Accum™ platform, which is integrated into multiple therapeutic modalities, including protein-based vaccines, antibody-drug conjugates, and cell-based therapies. The company does not currently report commercial-stage product revenue, with operations primarily funded through equity financing and strategic investments.

Operational activities are concentrated in research and development, including in vitro and in vivo studies, intellectual property management, and regulatory preparation for clinical trials. The company operates mainly in Canada, leveraging external research organizations and academic institutions for certain preclinical activities. Data inconclusive based on available public sources regarding any material revenue-generating partnerships or active joint ventures contributing to operating income.

Strategic Position & Investments

Strategically, Defence Therapeutics is focused on advancing its Accum™-enabled oncology and vaccine candidates toward clinical-stage development while expanding the applicability of its platform technology across additional therapeutic areas. Growth initiatives center on pipeline validation, intellectual property expansion, and potential licensing agreements with pharmaceutical or biotechnology partners.

The company has reported investments primarily in internal R&D and patent filings rather than large-scale acquisitions. Defence Therapeutics has highlighted oncology indications such as solid tumors and immune-resistant cancers as priority areas. While the company has referenced interest in emerging immunotherapy approaches, including enhanced antigen presentation and immune modulation, publicly available information does not conclusively confirm late-stage assets or material strategic acquisitions.

Geographic Footprint

Defence Therapeutics is headquartered in Canada, with its core operations and management based in Québec. The company’s research activities are primarily domestic, supported by Canadian academic and contract research infrastructure.

Internationally, Defence Therapeutics maintains a strategic outlook toward North American and European markets, particularly in relation to future clinical trials, regulatory pathways, and potential commercialization or licensing opportunities. At present, public disclosures indicate limited direct operational presence outside Canada, with international influence mainly through intellectual property filings and prospective partnerships.

Leadership & Governance

Defence Therapeutics was founded by scientists with backgrounds in immunology and biotechnology, reflecting a research-driven leadership culture. The company’s governance emphasizes platform innovation, translational research, and long-term value creation through intellectual property.

Key members of leadership include:

• Sébastien Plouffe – Chief Executive Officer
• Dr. Moutih Rafei – Chief Scientific Officer
• André Dorval – Chief Financial Officer
• Éric Tremblay – Director

The leadership team articulates a strategic vision centered on transforming immune-based therapies through improved intracellular delivery mechanisms. Data inconclusive based on available public sources regarding formalized ESG policies or board committee structures beyond standard public company governance practices.